SCHEMBL4239444

SCHEMBL4239444

CC1(C)C=Cc2cccc(C=O)c2O1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 1/20 0.39
PTPN1 P18031 2/20 0.39
HSD17B10 Q99714 2/20 0.36
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 2/20 0.35
TP53 P04637 2/20 0.35
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 2/20 0.34
THRB P10828 1/20 0.34
BLM P54132 1/20 0.34
IDO1 P14902 3/20 0.34
HTR2C P28335 2/20 0.34
ALDH1A1 P00352 3/20 0.33
HPGD P15428 2/20 0.33
NPC1 O15118 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13805579 0.75 HTR2C (0.55) PPARDPTPN1HSD17B10KDM4ETP53
SCHEMBL13422488 0.75 PTPN1 (0.43) PTPN1HSD17B10MEN1LMNAKMT2A
SCHEMBL15620453 0.74 KDM4E (0.36) PTPN1HSD17B10MEN1LMNAKMT2A
SCHEMBL5365370 0.74 PPARD (0.38) PPARDPTPN1HSD17B10KDM4ETP53
SCHEMBL4234524 0.73 PTPN1 (0.53) PTPN1HSD17B10IDO1PDE4D
SCHEMBL8679971 0.72 MAPT (0.53) HSD17B10MEN1LMNAKMT2AKDM4E
SCHEMBL8133127 0.72 ALDH1A1 (0.50) PPARDPTPN1HSD17B10MEN1LMNA
SCHEMBL30937310 0.72 ALDH1A1 (0.50) PPARDPTPN1HSD17B10MEN1LMNA
SCHEMBL16844642 0.69 PTPN1 (0.43) PTPN1HSD17B10MEN1LMNAKMT2A
SCHEMBL30277636 0.68 PTPN1 (0.48) PPARDPTPN1MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156575-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2009-06-18 US disclosed
US-20090156575-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2009-06-18 US disclosed
US-20090156575-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2009-06-18 US disclosed
CN-101305005-A Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases ASTRAZENECA AB (SE) 2008-11-12 CN disclosed
EP-1926730-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2008-06-04 EP disclosed
WO-2007030061-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2007-03-15 WO disclosed
WO-2007030061-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156575-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES CCR8, CCR1, CCR10 PPARD 272/4885PTPN1 2000/4885HSD17B10 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.